Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaucoma in perspective

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

- PMLiVE

Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for adults with urothelial carcinoma

UC accounts for approximately 90% of all bladder cancers, the ninth most common cancer globally

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders

Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

Medical devices – the rapidly evolving landscape of healthcare and technology

How choosing market entry in one country over another can impact the success of your medical device

- PMLiVE

Through the looking-glass: AI in medical imaging

By Cathy Chow

- PMLiVE

Going deeper than the data: integrating neuromarketing for customer engagement

By Nicole Luciano

- PMLiVE

Medscape Oncology Launches Inaugural Medscape Fellows Program at ASCO 2024

Medscape Oncology is excited to announce the launch of the first-ever Medscape Fellows Program at the 2024 ASCO meeting in Chicago, Illinois. This groundbreaking program aims to nurture young oncology...

Medscape Education Global

- PMLiVE

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study

Datopotamab deruxtecan demonstrated a clinically meaningful overall survival improvement in NSCLC patients

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Merck presents positive results for Keytruda plus chemotherapy in breast cancer

Triple-negative breast cancer accounts for 24% of all newly diagnosed cancers worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links